Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

August 09, 2011; 77 (6) Clinical/Scientific Notes

Evaluation of soluble HLA-G as a biomarker for multiple sclerosis

A. Waschbisch, R. Sandbrink, H.-P. Hartung, L. Kappos, S. Schwab, C. Pohl, H. Wiendl
First published July 27, 2011, DOI: https://doi.org/10.1212/WNL.0b013e318228c14d
A. Waschbisch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Sandbrink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.-P. Hartung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Kappos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Schwab
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Pohl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Wiendl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Evaluation of soluble HLA-G as a biomarker for multiple sclerosis
A. Waschbisch, R. Sandbrink, H.-P. Hartung, L. Kappos, S. Schwab, C. Pohl, H. Wiendl
Neurology Aug 2011, 77 (6) 596-598; DOI: 10.1212/WNL.0b013e318228c14d

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
190

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Human leukocyte antigen G (HLA-G) is a nonclassical HLA class I antigen that stands out for its immune regulatory properties. First recognized as a mediator of tolerance at the feto-maternal interface, HLA-G is considered a key molecule in protecting target tissue from autoaggressive inflammation.1 High serum levels of soluble HLA-G (sHLA-G) were found to predict graft acceptance in allotransplantation, whereas low levels seem to increase the risk of autoimmunity and account for higher disease activity in autoimmune diseases (e.g., rheumatoid arthritis).1 To evaluate its potential use as a biomarker in multiple sclerosis (MS), we analyzed sHLA-G serum protein in a large cohort of patients with clinically isolated syndrome (CIS) who developed MS during the 5-year observation period of the Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) trial.2

Methods.

BENEFIT was a placebo-controlled phase III trial of interferon-β (IFNβ)–1b in patients with CIS.2 The study design and outcomes of BENEFIT have been reported elsewhere.2 All patients underwent Expanded Disability Status Scale (EDSS) assessment and brain MRI on a regular basis. The present study focused on patients who reached clinically definite MS (CDMS) during the trial (n = 209). From these patients, a total of 555 serum samples and 435 MRI scans were analyzed. Quantification of sHLA-G was performed using a commercially available ELISA kit (Exbio, Prague, Czech Republic). Nonparametric tests and Cox proportional hazards regression were used in the statistical analysis. A 2-sided p value < 0.05 was considered significant.

Results.

The analysis of “basal” sHLA-G serum levels in untreated patients yielded a highly heterogeneous result (figure 1A). While sHLA-G was undetectable in 22.1% of patients, 12.7% had excessive amounts of sHLA-G serum …

View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Topics Discussed

  • All Immunology
  • Autoimmune diseases
  • Multiple sclerosis

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise